Fenbufen Tablets

[Pharmacology and Toxicology] This product is a long-acting non-steroidal anti-inflammatory drug. After entering the body, it is metabolized into diphenyl ethyl ester, which has the activity of inhibiting cyclooxygenase, reducing the synthesis of prostaglandins and taking effect. Animal experiments show that the anti-inflammatory and analgesic effect of this product is weaker than indomethacin, but stronger than aspirin. Results of acute toxicity test: oral LD50 of rats is 200-720 mg/kg, and intraperitoneal injection LD50 is 265-575 mg/kg; oral LD50 of mice is 795-1673 mg/kg, and intraperitoneal injection LD50 is 506-811 mg/kg. [Pharmacokinetics] About 80% of this product is absorbed 2 hours after oral administration. The blood concentration of active metabolites reaches a peak in 6-8 hours. T1/2 is relatively long, about 7 hours, but the concentration can still be measured in the blood for 72 hours. The plasma protein binding rate is 98%-99%. 66% is excreted in urine, 10% is excreted in the respiratory tract, and 10% is excreted in feces.

The main ingredients of this product are: Fenbufen

This product is white or off-white tablets.

It is used to treat rheumatoid arthritis, rheumatic arthritis, osteoarthritis, spondyloarthropathies, and gouty arthritis. It can also be used for toothache, postoperative pain, and traumatic pain.

Oral (1) Usual dosage for adults: 0.6 g per day, taken once or twice. The total daily dosage for adults should not exceed 1.0 g. (2) Usual dosage for children: Not yet established.

The adverse reactions of this product are mainly gastrointestinal reactions, manifested as stomach pain, burning sensation in the stomach, nausea, and a few serious adverse reactions include gastric ulcer, bleeding, and even perforation. Dizziness, rash, mild decrease in white blood cell count, and mild increase in serum transferase are less common.

(1) Patients who are allergic to this product are contraindicated. (2) Patients with peptic ulcer, severe liver and kidney damage, or aspirin-induced asthma are contraindicated.

Precautions for children: Do not use. Precautions for pregnancy and lactation: Do not use. Precautions for the elderly: Elderly patients should be aware of renal toxicity due to decreased renal function.

Not yet clear

Keep away from light and store in sealed container.

0.3g

36 months

Shanghai Yurui BIOTECHNOLOGY (Anyang) Pharmaceutical Co., Ltd.

• Founded in:

  2005-04-18

• Address:

  Anyang Hanling Industrial Park

• Tax NO.:

  914105227880639115

• Registered Funds:

  81.66 million yuan

• Website:

  Log in to view

• Email:

  Log in to view